XELJANZ: Pfizer vs Teva Disputan por patente

 

_Pfizer and Teva Pharmaceutical  have agreed to settle a patent dispute linked to the rheumatoid arthritis therapy Xeljanz, Bloomberg reports.

_No details were given on the stipulation of dismissal, which was filed on Tuesday and is yet to be approved in federal court in Wilmington, Delaware.

_Pfizer  has claimed that Teva’s  proposed generic version of 11-milligram Xeljanz XR violated its patents on the drug.

_In January, the company also challenged Aurobindo Pharma’s plans to introduce generic versions of Xeljanz (tofacitinib), arguing that 5- and 10-mg tablets infringed two patents. That case is also pending in Delaware.

_Xeljanz generated ~$2.4B in sales for Pfizer in 2020, up from ~$2.2B in the previous year.

_However, the treatment belonging to the class of drugs called Janus kinase (JAK) inhibitors is plagued by safety concerns.

Ver